Navigating the Headwaters of Intellectual Property Risk in the Pharmaceutical Industry

Simon Jenner, Chief Legal Officer, Acella Pharmaceuticals, LLC, USA

Intellectual property litigation may feel like familiar ground to many competitors in the pharmaceutical drug, medical device, nutraceutical, and other prescription markets. Yet intellectual property laws frequently interact in ways that surprise even well-seasoned competitors, wreaking havoc on key business metrics and ratios. With that concern very much in view, this paper proposes a few considerations in managing towards a more effective and holistic litigation risk management strategy that considers the product and its rivals, relevant business objectives, and the ultimate pathway to success (however that may be defined).

Read full paper Subscribe to the IICJ
USA Intellectual Property Pharmaceutical June 2016 Vol. 9, No. 35, Spring 2016

Simon Jenner

More

Simon Jenner is Chief Legal Officer for Acella Pharmaceuticals, LLC and Avion Pharmaceuticals, LLC, which are leaders in several important markets. He has significant experience in complex transactions and litigation, including intellectual property and L

Acella Pharmaceuticals, LLC

More

Acella Pharmaceuticals, LLC and Avion Pharmaceuticals, LLC are affiliated, specialty pharmaceutical companies located in Alpharetta, Georgia, a part of the larger Atlanta Metropolitan Area. Acella markets, sells and distributes a broad portfolio of non-br

USA Intellectual Property Pharmaceutical June 2016 Vol. 9, No. 35, Spring 2016